Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of GOLT1B inhibitor in preparation of medicine for treating colorectal cancer

A colorectal cancer and inhibitor technology, applied in the field of medicine and biology, can solve the problem of limited applicable population

Active Publication Date: 2021-01-15
THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the two types of targeted drugs targeting EGFR and VEGFR are limited to a limited number of people, for example, about 40% of patients with K-ras gene mutations are ineffective for cetuximab treatment
The screening of Golgi membrane protein GOLT1B and its application in the early diagnosis of colorectal cancer have not been reported at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GOLT1B inhibitor in preparation of medicine for treating colorectal cancer
  • Application of GOLT1B inhibitor in preparation of medicine for treating colorectal cancer
  • Application of GOLT1B inhibitor in preparation of medicine for treating colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 GOLT1B is significantly highly expressed in colorectal cancer

[0026] Using the Oncomine online database to analyze the mRNA data related to colorectal cancer, it was found that GOLT1B was significantly highly expressed in colorectal cancer ( figure 1 , figure 2 ); CPTAC (Clinical Proteomic Tumor Analysis Consortium, Clinical Proteomic Tumor Analysis Collaborative Group) data showed that the protein expression level of GOLT1B in colorectal cancer patients was significantly higher than that in the normal group ( image 3 ); immunohistochemical analysis was consistent with the results of the database ( Figure 4 ); while patients with high expression of GOLT1B had a lower survival rate ( Figure 5 ).

Embodiment 2

[0027] The cultivation of embodiment 2 cells

[0028] Colorectal cancer cell lines HCT116 and RKO were preserved by the Institute of Gastroenterology, Sun Yat-Sen University. HCT116 used McCoy's 5a Medium Modified (Gibco, USA) medium containing 10% fetal calf serum (Invitrogen, USA), and RKO used 10% fetal bovine serum (Invitrogen, USA) containing 10% fetal bovine serum (Invitrogen, USA). The MEM (Gibco, USA) medium of bovine serum (Invitrogen, USA) was cultured in a 37° C. constant-temperature humid incubator containing 5% carbon dioxide.

Embodiment 3

[0029] Embodiment 3 inhibitor suppresses GOLT1B gene expression

[0030] The HCT116 and RKO cells cultured in Example 2 were inoculated into a six-well plate containing an appropriate amount of complete medium, and the inoculation amount was 1×10 6 cells, so that the cell density during transfection can reach 30%-50%, use the siRNA of GOLT1B (the sequence of siRNA is shown in Table 1) and the control group si-NC to transiently transfect HCT116 and RKO cells, siRNA and si-NC The final concentration of NC was 5OnM. Replace with fresh complete medium without antibiotics 12 hours after transfection.

[0031] After the transfected cells were cultured for 48 hours, the total RNA was extracted to detect the expression level of the target GOLT1B by RT-PCR. The results were as follows: Image 6 As shown, the cells showing the transfection inhibitor (treated group) had significantly lower expression levels of the target than the control group.

[0032] Table 1 Sequence information of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medical biology, in particular to application of a GOLT1B inhibitor in preparation of a medicine for treating colorectal cancer. Scratch and invasion experimentsshow that the migration and invasion performance of colorectal cancer cells treated by the GOLT1B inhibitor are remarkably reduced. Therefore, the GOLT1B inhibitor provided by the invention can inhibit metastasis of the colorectal cancer to improve the treatment effect of the colorectal cancer.

Description

technical field [0001] The invention relates to the field of medicine and biology, in particular to the application of GOLT1B inhibitors in the preparation of medicines for treating colorectal cancer. Background technique [0002] Colorectal cancer (CRC) is the third most common malignant tumor in my country, with approximately 1.2 million new cases and nearly 700,000 deaths worldwide each year; approximately 30% to 40% of patients are diagnosed with advanced disease at the time of first diagnosis. rectal cancer. About 50% of patients with advanced CRC have recurrence and metastasis after treatment, which is an important reason that affects the efficacy of clinical treatment and leads to death. There is an urgent need for new treatments for colorectal cancer. [0003] The vesicle transporter GOLT1B is involved in the transport of various proteins, and its role in tumors has not been reported so far. Through research, it was found that GOLT1B was significantly highly expres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/7088A61P1/00A61P35/00
CPCA61K45/00A61K31/7088A61P1/00A61P35/00
Inventor 杨孜欢刘腾飞刘彬彬冯杏芝刘依婷蒋雪飞
Owner THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com